Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Cited In for PubMed (Select 15817922)

1.

Advances in understanding pituitary tumors.

Kopczak A, Renner U, Karl Stalla G.

F1000Prime Rep. 2014 Jan 2;6:5. doi: 10.12703/P6-5. eCollection 2014. Review.

2.

Update in the medical therapy of Cushing's disease.

Nieman LK.

Curr Opin Endocrinol Diabetes Obes. 2013 Aug;20(4):330-4. doi: 10.1097/MED.0b013e3283631809. Review.

3.

Pharmacoeconomic aspects of the treatment of pituitary gland tumours.

Sowiński J, Sawicka N, Piątek K, Zybek A, Ruchała M.

Contemp Oncol (Pozn). 2013;17(2):137-43. doi: 10.5114/wo.2013.34616. Epub 2013 Apr 29.

4.

New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.

Fleseriu M, Petersenn S.

J Neurooncol. 2013 Aug;114(1):1-11. doi: 10.1007/s11060-013-1151-1. Epub 2013 May 15. Review.

5.

Peptide receptor targeting in cancer: the somatostatin paradigm.

Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, Corsaro A, Villa V, Nizzari M, Florio T.

Int J Pept. 2013;2013:926295. doi: 10.1155/2013/926295. Epub 2013 Feb 7.

6.

Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics.

Pozza C, Graziadio C, Giannetta E, Lenzi A, Isidori AM.

J Oncol. 2012;2012:685213. doi: 10.1155/2012/685213. Epub 2012 Aug 9.

7.

Medical management of Cushing's disease: what is the future?

Fleseriu M, Petersenn S.

Pituitary. 2012 Sep;15(3):330-41. doi: 10.1007/s11102-012-0397-5. Review.

8.

Treatment Options in Cushing's Disease.

Rizk A, Honegger J, Milian M, Psaras T.

Clin Med Insights Oncol. 2012;6:75-84. doi: 10.4137/CMO.S6198. Epub 2012 Jan 11.

9.

Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion.

de Bruin C, Hofland LJ, Nieman LK, van Koetsveld PM, Waaijers AM, Sprij-Mooij DM, van Essen M, Lamberts SW, de Herder WW, Feelders RA.

J Clin Endocrinol Metab. 2012 Feb;97(2):455-62. doi: 10.1210/jc.2011-1264. Epub 2011 Nov 16.

10.

Treatment of Cushing disease: overview and recent findings.

Mancini T, Porcelli T, Giustina A.

Ther Clin Risk Manag. 2010 Oct 21;6:505-16. doi: 10.2147/TCRM.S12952.

11.

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.

Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M.

BMC Endocr Disord. 2010 May 17;10:10. doi: 10.1186/1472-6823-10-10.

12.

Medical treatment of Cushing's disease: Overview and recent findings.

Praw SS, Heaney AP.

Int J Gen Med. 2009 Dec 29;2:209-17.

13.

Pituitary somatostatin receptor signaling.

Ben-Shlomo A, Melmed S.

Trends Endocrinol Metab. 2010 Mar;21(3):123-33. doi: 10.1016/j.tem.2009.12.003. Epub 2010 Feb 9. Review.

14.

Future treatment strategies of aggressive pituitary tumors.

Lamberts SW, Hofland LJ.

Pituitary. 2009;12(3):261-4. doi: 10.1007/s11102-008-0154-y. Review.

15.

Hypocortisolemic clamp unmasks jointly feedforward- and feedback-dependent control of overnight ACTH secretion.

Iranmanesh A, Veldhuis JD.

Eur J Endocrinol. 2008 Nov;159(5):561-8. doi: 10.1530/EJE-08-0417. Epub 2008 Aug 19.

16.

Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing's disease.

de Bruin C, Hanson JM, Meij BP, Kooistra HS, Waaijers AM, Uitterlinden P, Lamberts SW, Hofland LJ.

Endocrinology. 2008 Sep;149(9):4357-66. doi: 10.1210/en.2008-0244. Epub 2008 May 15.

17.

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M.

J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62. doi: 10.1210/jc.2007-2734. Epub 2008 Apr 15. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk